Martine Jandrot-Perrus

This inventor holds 9 USPTO granted patents and 1 published patent application and 5 EPO patents. Top assignees: National Institute of Health and Medical Research, Acticor Biotech, Université Paris Diderot-Paris 7. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martine Jandrot-Perrus. Retrieved from https://idiyas.com/inventor/martine-jandrot-perrus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 66.7

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 18(Granted Patents)

Location History:

Paris Cedex, FR (2013)
Paris, FR (2015 - 2018)
Vanves, FR (2006 - 2023)

Company Filing History:

7 out of 1,853

National Institute of Health and Medical Research

Université Paris Diderot-Paris 7

patents

4. 3 out of 3

Universite Paris-Xiii

patents

5. 2 out of 102

Université Paris-Saclay

patents

6. 1 out of 23

Inserm (Institut National De La Santé Et De La Recherche Médicale)

patents

7. 1 out of 855

Millennium Pharmaceuticals Limited

Universite Paris Cité

patents

10. 1 out of 8

Université Paris Diderot

patents

11. 1 out of 8

Universite Paris Xiii Paris-Nord

patents

12. 1 out of 43

Université Paris-Sud 11

patents

where one patent can have more than one assignee

Years Active: 2006-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630631 - INHIBITION OF PLATELET AGGREGATION USING ANTI-HUMAN GPVI ANTIBODIES (2026-05-19),

2. 11692033 - Inhibition of platelet aggregation using anti-human GPVI antibodies (2023-07-04),

3. 10842870 - Anti-human GPVI antibodies and uses thereof (2020-11-24),

4. 9999679 - Aminofucoidan as a vector for fibrinolysis in thrombotic diseases (2018-06-19),

5. 9045540 - Anti-glycoprotein VI scFv fragment for treatment of thrombosis (2015-06-02),

6. 9045538 - Anti-glycoprotein VI scFv fragment for treatment of thrombosis (2015-06-02),

7. 9029095 - Method and kits for determining platelet susceptibility to activation in a patient (2015-05-12),

8. 8466258 - Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis (2013-06-18),

9. 6989144 - Glycoprotein VI antibodies and uses thereof (2006-01-24),

Title: Martine Jandrot-Perrus: Innovator in Medical Research

Introduction

Martine Jandrot-Perrus is a prominent inventor based in Vanves, France. She has made significant contributions to the field of medical research, particularly in the area of platelet aggregation and related conditions. With a total of 9 patents to her name, her work has had a substantial impact on the medical community.

Latest Patents

Among her latest patents is the invention titled "Inhibition of platelet aggregation using anti-human GPVI antibodies." This invention relates to an isolated humanized protein that binds to human Glycoprotein VI (hGPVI) for treating GPVI-related conditions. The isolated humanized protein is designed to be administered to subjects for a duration of at least 2 hours, preferably between 4 to 6 hours. Another notable patent is "Anti-human GPVI antibodies and uses thereof," which focuses on humanized anti-human GPVI antibodies and their applications.

Career Highlights

Martine has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Acticor Biotech. Her career reflects a commitment to advancing medical science and improving patient outcomes through innovative research.

Collaborations

Throughout her career, Martine has collaborated with notable professionals in her field, including Philippe Billiald and Julien Muzard. These collaborations have further enriched her research and contributed to her success as an inventor.

Conclusion

Martine Jandrot-Perrus stands out as a leading figure in medical innovation, with her patents paving the way for advancements in the treatment of platelet-related conditions. Her dedication to research and collaboration continues to inspire future innovations in the medical field.

Profile summary based on public USPTO records.